BACKGROUND: Data on the outcomes of older adults receiving peritoneal dialysis (PD), especially those who are dependent and have multiple comorbidities, are scarce. METHODS: In a retrospective cohort study, we compared older adults (≥65 years) with stage 5 chronic kidney disease receiving PD (PD group) with those receiving conservative management (conservative group). Baseline characteristics (demographics and clinical, functional, socioeconomic, and laboratory parameters) were collected, and study outcomes (patient survival, emergency hospitalization, institutionalization, and palliative and end-of-life care) were compared between groups. RESULTS: We included 199 eligible participants aged 65-90 years (mean ± standard deviation 73.8 ± 5.4 years; 157 in the PD group and 42 in the conservative group). The PD group had a longer survival (median [interquartile range]: 3.75 [2.49-5.25] vs 2.35 [1.13-3.71] years, p < .001), lower emergency hospitalization rates (1.63 [0.82-2.92] vs 3.51 [1.06-7.16] per person-year, p < .01) and hospital days (16.17 [6.29-43.32] vs 38.01 [6.75-76.56] days per person-year, p = .03), and no increased risk of institutionalization compared with the conservative group. Age (hazard ratio [HR] for 1-year increase 1.06, 95% confidence interval [CI] 1.02-1.10), modified Charlson's Comorbidity Index (HR 1.36, 95% CI 1.18-1.56), impairment in basic activities of daily living (HR 2.11, 95% CI 1.28-3.46), and emergency dialysis (HR 1.67, 95% CI 1.11-2.53) were independent predictors of mortality in the PD group. CONCLUSION: PD is a viable treatment option in older adults with stage 5 chronic kidney disease. Age alone should not preclude dialysis. Comprehensive geriatric assessment can prognosticate and facilitate shared decision making to commence dialysis in older adults.
BACKGROUND: Data on the outcomes of older adults receiving peritoneal dialysis (PD), especially those who are dependent and have multiple comorbidities, are scarce. METHODS: In a retrospective cohort study, we compared older adults (≥65 years) with stage 5 chronic kidney disease receiving PD (PD group) with those receiving conservative management (conservative group). Baseline characteristics (demographics and clinical, functional, socioeconomic, and laboratory parameters) were collected, and study outcomes (patient survival, emergency hospitalization, institutionalization, and palliative and end-of-life care) were compared between groups. RESULTS: We included 199 eligible participants aged 65-90 years (mean ± standard deviation 73.8 ± 5.4 years; 157 in the PD group and 42 in the conservative group). The PD group had a longer survival (median [interquartile range]: 3.75 [2.49-5.25] vs 2.35 [1.13-3.71] years, p < .001), lower emergency hospitalization rates (1.63 [0.82-2.92] vs 3.51 [1.06-7.16] per person-year, p < .01) and hospital days (16.17 [6.29-43.32] vs 38.01 [6.75-76.56] days per person-year, p = .03), and no increased risk of institutionalization compared with the conservative group. Age (hazard ratio [HR] for 1-year increase 1.06, 95% confidence interval [CI] 1.02-1.10), modified Charlson's Comorbidity Index (HR 1.36, 95% CI 1.18-1.56), impairment in basic activities of daily living (HR 2.11, 95% CI 1.28-3.46), and emergency dialysis (HR 1.67, 95% CI 1.11-2.53) were independent predictors of mortality in the PD group. CONCLUSION: PD is a viable treatment option in older adults with stage 5 chronic kidney disease. Age alone should not preclude dialysis. Comprehensive geriatric assessment can prognosticate and facilitate shared decision making to commence dialysis in older adults.
Authors: Susan P Y Wong; Saritha Boyapati; Ruth A Engelberg; Bjorg Thorsteinsdottir; Janelle S Taylor; Ann M O'Hare Journal: Am J Kidney Dis Date: 2019-09-27 Impact factor: 8.860
Authors: Wouter R Verberne; A B M Tom Geers; Wilbert T Jellema; Hieronymus H Vincent; Johannes J M van Delden; Willem Jan W Bos Journal: Clin J Am Soc Nephrol Date: 2016-03-17 Impact factor: 8.237
Authors: Ikumi Okamoto; Sarah Tonkin-Crine; Hugh Rayner; Fliss E M Murtagh; Ken Farrington; Fergus Caskey; Charles Tomson; Fiona Loud; Roger Greenwood; Donal J O'Donoghue; Paul Roderick Journal: Clin J Am Soc Nephrol Date: 2014-11-11 Impact factor: 8.237
Authors: Marije H Kallenberg; Hilda A Kleinveld; Friedo W Dekker; Barbara C van Munster; Ton J Rabelink; Marjolijn van Buren; Simon P Mooijaart Journal: Clin J Am Soc Nephrol Date: 2016-06-24 Impact factor: 8.237
Authors: Susan P Y Wong; Margaret K Yu; Pamela K Green; Chuan-Fen Liu; Paul L Hebert; Ann M O'Hare Journal: Am J Kidney Dis Date: 2018-01-10 Impact factor: 8.860
Authors: Susan P Y Wong; Lynne V McFarland; Chuan-Fen Liu; Ryan J Laundry; Paul L Hebert; Ann M O'Hare Journal: JAMA Intern Med Date: 2019-03-01 Impact factor: 21.873
Authors: Mario Pacilio; Roberto Minutolo; Carlo Garofalo; Maria Elena Liberti; Giuseppe Conte; Luca De Nicola Journal: J Nephrol Date: 2015-11-19 Impact factor: 3.902
Authors: Roman Reindl-Schwaighofer; Alexander Kainz; Michael Kammer; Alexandra Dumfarth; Rainer Oberbauer Journal: PLoS One Date: 2017-07-24 Impact factor: 3.240
Authors: Michael K Sullivan; Alastair J Rankin; Bhautesh D Jani; Frances S Mair; Patrick B Mark Journal: BMJ Open Date: 2020-06-30 Impact factor: 2.692
Authors: Wouter R Verberne; Janneke Dijkers; Johannes C Kelder; Anthonius B M Geers; Wilbert T Jellema; Hieronymus H Vincent; Johannes J M van Delden; Willem Jan W Bos Journal: BMC Nephrol Date: 2018-08-16 Impact factor: 2.388